On 27th July 2020, Ministry of Electronics and Information Technology (MeitY) introduced PLI or Production Linked Incentive Scheme for pharmaceutical manufacturing. Which of the following points is/are NOT covered under this scheme?
1. Production Linked Incentives of upto INR 6,940 crores have been approved
2. A financial incentive will be given to eligible manufacturers of identified 41 eligible products which covers 53 APIs, for 6 years, committed investment and sales made by selected applicant for the eligible products.
3. The Net Worth of the Applicant (including that of Group Companies), as on the date of application, shall not be less than 30% of the total committed investment.
4. The scheme shall be operational during the period FY 2020-2021 to 2024-2025
Select the correct answer using the code given below.

Correct option is A

The correct answer is (a) C (Statements 3 and 4 are NOT covered)
Explanation:
· The PLI scheme for pharmaceuticals was launched by the Department of Pharmaceuticals, not MeitY.
· It provides incentives up to INR 6,940 crore to manufacturers for 53 APIs across 41 products.
· The incentive is for a period of 6 years.
· There is no such mandatory condition of 30% net worth.
· The scheme is operational from FY 2020-21 to 2028-29, not 2024-25.
Information Booster:
· The scheme aims to reduce dependence on Chinese imports for key APIs.
· It is part of the Aatmanirbhar Bharat initiative.
· It provides 5%–20% incentives on incremental sales.
· It encourages greenfield investments in API manufacturing.
· PLI scheme has also been extended to other sectors like electronics, telecom, and textiles.
Additional Information:
• Approved in March 2020 for pharmaceuticals with revised guidelines in July 2020.
• The PLI model was later extended to 14 major sectors by the central government.